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Abstract
OBJECTIVE: The objective of this systematic review is to determine whether or not dabigatran
150 mg twice daily is non-inferior to warfarin for the prevention of stroke in those with atrial
fibrillation with similar rates of bleeding events.

STUDY DESIGN: Review of 3 English language primary studies. All three trials were
randomized controlled trials which were blinded for those receiving dabigatran and un-blinded
for those receiving warfarin.

DATA SOURCES: Articles were found using PUBMED and COCHRANE databases.

OUTCOME MEASURED: The primary outcomes of these studies were either incidence of
stroke or systemic embolism and/or major bleeding events.

RESULTS: The RE-LY study determined that rates of stroke or systemic embolism were 1.11%
per year in the group who received 150 mg of dabigatran twice daily and 1.69% per year in those
who received dose adjusted warfarin (CI =95%; P=<0.0001). The incidence of major bleeding
was 3.11% per year in those who received dabigatran 150 mg twice daily and 3.36% per year in
the warfarin group (P=0.003). The RE-COVER study found that recurrent venous
thromboembolism occurred in 2.4% of patients who received dabigatran and 2.1% of those who
received warfarin (CI= 95%, P= <0.001). Incidence of major bleeding was found in 1.6% of
patients in the dabigatran 150 mg group and a slightly higher percentage of 1.9% of those in the
warfarin group (CI=95%). The PETRO study determined that in the 150 mg dabigatran group
without aspirin, 9% of patients reported clinically relevant bleeding with zero thromboembolic
events. In patients who received dose adjusted warfarin without aspirin, 5.7% of patients
experienced clinically relevant bleeding with also no reported thromboembolic events (P=0.01).

CONCLUSION: The systemic review of all three randomized controlled trials indicates that
dabigatran 150 mg twice a day is a safe, effective, and more convenient alternative to warfarin to
prevent stroke in patients with atrial fibrillation.
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INTRODUCTION
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting more
than two million patients throughout the United States.1 Each year, more than 300,000 new
cases are diagnosed.2 Atrial fibrillation comprises nearly $6 – 7 billion in direct medical
expenditures and accounts for approximately 350,000 hospitalizations annually.3 Research has
shown that when comparing medical costs of a non-AF patient to an AF patient, total annual
direct medical costs of those with AF are close to 5 times greater than that of those without the
arrhythmia.4 Medical costs in patients with this condition may be so high secondary to the nature
and risks of the arrhythmia.
In episodes AF, the normal electrical impulses which are generated through the sinoatrial
node become disorganized by electrical impulses that originate in other areas of the heart,
possibly the pulmonary veins. This “chaotic” electrical activity results in the muscle of the atria
fibrillating instead of producing a coordinated contraction of the chambers. Unbalanced
conduction of the ventricles also produces an irregularly irregular ventricular rate. Atrial
fibrillation can be acute, occurring in episodes lasting only minutes to weeks, or may be chronic,
becoming permanent in nature.5
Many patients are asymptomatic during an episode of AF. Others may have more marked
symptoms such as palpitations, syncope, chest pain, or shortness of breath. Atrial fibrillation is
commonly diagnosed through a simple electrocardiogram which will show absence of P-waves
and the presence of an irregularly irregular ventricular rate. Risk factors for developing AF
include heart failure, hypertensive cardiovascular disease, coronary artery disease, valvular heart
disease, and recent myocardial infarction.6

AF is commonly treated with medications to control heart rate and rhythm to revert the
patient back to normal sinus rhythm. Some surgical or catheter based therapies can also be used.
Because up to 5% of patients with chronic atrial fibrillation have at least one embolic episode per
year, there is a need for these patients to be anticoagulated.7 Currently, warfarin, a vitamin K
antagonist, is the first line treatment being used for prophylactic anticoagulation in this
population. However, due to increased risk of patient hemorrhage during usage, monthly
laboratory monitoring and numerous drug and food interactions, a new oral anticoagulant drug is
needed that has a similar or improved safety profile, as well as better convenience for patients
who must be on lifelong anticoagulant therapy. Dabigatran is a new oral direct thrombin
inhibitor that is being evaluated for the prevention of stroke in those patients with AF with a
similar incidence of hemorrhage.
OBJECTIVE
The objective of this systematic review is to determine whether or not dabigatran 150mg
is non-inferior to warfarin for the prevention of stroke in those with atrial fibrillation with a
similar safety profile. To date, there are few anticoagulant drugs, other than warfarin, that are
approved to prevent stroke in patients with AF. Dabigatran is the first oral direct thrombin
inhibitor that has been approved to compete with warfarin to prevent stroke in those with AF
with similar frequency of bleeding.
METHODS
The three studies that are included in this review are randomized controlled trials
comparing the efficacy of dabigatran 150 mg to dose adjusted warfarin for the prevention of
stroke in those atrial fibrillation with similar incidence of hemorrhage.

Connolly et al. conducted the RE-LY study, a randomized controlled trial to assess the
efficacy of dabigatran 150 mg versus warfarin. The trial was non-inferior, double blinded for
those in the dabigatran group and unblinded for those in the warfarin group due to the need for
adjusted INR levels. The study focused on 18,113 patients with atrial fibrillation documented on
echocardiography with one of the following: previous stroke or TIA, left ventricular ejection
fraction less than 40%, New York Heart Association Class II or higher, age of 75, or age of 64 –
74 with diabetes, hypertension, or coronary artery disease. The intervention addressed in the
study included dabigatran 150 mg twice daily to prevent stroke or systemic embolism in those
with atrial fibrillation. The comparison group was dose adjusted warfarin. The primary
outcomes of this study were incidence of stroke or systemic embolism, with secondary efficacy
endpoints consisting of major bleeding, hemorrhagic stroke, and mortality rate.
Shulman at el. conducted the RE-COVER study, a double blinded randomized controlled
trial to determine the efficacy of dabigatran 150mg versus warfarin for the treatment of acute
venous thromboembolism as well as rates of hemorrhage. This study included 2,539 patients 18
years of age or older who had acute, symptomatic, objectively verified proximal deep vein
thrombosis of the legs or pulmonary embolism and for whom 6 months of anticoagulant therapy
was considered to be an appropriate treatment. Dabigatran 150 mg twice daily, after a median of
9 days of initial parenteral anticoagulation, was the intervention addressed in this study. The
comparison group was comprised of dose adjusted warfarin after initial parenteral
anticoagulation. The primary outcome measured in this study was 6-month incidence of
confirmed venous thromboembolism. Secondary outcomes were major bleeding events, acute
coronary syndromes, other adverse events, and results of liver function tests.

Ezekowitz et al. conducted a similar randomized controlled trial which was double blind
in respect to dabigatran, but open label regarding aspirin and warfarin. The population addressed
in the PETRO study was patients with atrial fibrillation at high risk for thromboembolic events
or AF with coronary artery disease plus 1 or more of the following: hypertension, diabetes,
symptomatic heart failure, left ventricular dysfunction, or previous stroke or TIA. Dabigatran
was administered at 50 mg, 150 mg, or 300 mg, twice daily with either no aspirin, 81 mg or 325
mg aspirin once daily. The dabigatran 150 mg dose twice daily without aspirin was the main
focus for this review. These interventions were compared to dose adjusted warfarin. The primary
outcome addressed was frequency of bleeding events and secondary outcomes were incidence of
stroke and/or systemic thromboembolism.
These studies were found by the author using PubMed and Cochrane databases. The key
words dabigatran, warfarin and atrial fibrillation were used in the literature searches to find
articles that were published in English in peer-reviewed journals dated between 2007 – 2009.
The articles were chosen if they were relevant, valid, and the outcomes of the studies were
comprised of evidence that mattered to the patients (POEMS – Patient Oriented Evidence that
Matters). The articles selected were those that met the following criteria: POEM, randomized
controlled trial, a diagnosis of atrial fibrillation based upon electrocardiogram, or a primary
outcome of stroke or major bleeding. Any studies not meeting these criteria were excluded from
this review. P-values, number needed to treat (NNT), number needed to harm (NNH), relative
risk reduction (RRR), absolute risk reduction (ARR), control event rate (CER), and experimental
event rate (EER) were the statistics used and reported in the studies. Table 1 shows the
demographics of the three studies included in this review.

Table 1. Demographics of included studies
Study
Connolly
(2009)
RE-LY

Type
Double
blind RCT
with
respect to
dabigatran
;
unblinded
in respect
to
warfarin

# Pts
18,113

Age (yrs)
Mean age 71

Inclusion Criteria
-Patients with AF
documented on EKG
with 1 of the
following:
-Previous stroke or
transient ischemic
attack
-LFEV less than 40%
-New York Heart
Association Class II
or higher
-Age of 75
-Age of 64 – 74 with
DM, HTN, or CAD

Exclusion Criteria
-Presence of severe
valve disorder
-Stroke w/in 14 days
or severe stroke
with in 6 mo before
screening
-Condition that
increased risk of
hemorrhage
-CrCl <30
-Acute liver disease
-Pregnancy

W/D
0

Intervention
Dabigatran 150
mg BID

Schulman
(2009)
RE-COVER

Double
blind RCT

2,550

55.0±15.8
Dabigatran

Patients 18 years of
age or older who had
acute, symptomatic,
objectively verified
proximal deep vein
thrombosis of the
legs or pulmonary
embolism and for
whom 6 months of
anticoagulant therapy
was considered to be
an appropriate
treatment

-Symptoms longer
than 14 days
- PE with instability
-Other indication for
warfarin
-Unstable CV
disease
-High bleeding risk
-Liver disease with
AST > 2x upper
limit
-CrCl <30
-Pregnancy
-Need for
antiplatelet therapy
-CI to heparin or
contrast

5

Dabigatran
150mg BID

-Patients with AF at
high risk for
thromboembolic
events
-AF with CAD plus 1
of the following:
-HTN, DM,
symptomatic HF, LV
dysfunction, previous
stroke or TIA

-Mitral stenosis
-Prosthetic heart
valves
-Cardioversion
-Recent MI, stroke
or TIA
Coronary stent in
last 6 mo
-CI to
anticoagulation
-severe hemorrhage
in last 6 mo
-Renal impairment
-Abnl liver function
-Pregnancy
-Investigation drug
use in last 30 days

65

Dabigatran 50
mg, 150 mg, or
300 mg BID,
with either no
aspirin, 81 mg
or 325 mg
aspirin daily

54.4±16.2
Warfarin

Ezekowitz
(2007)
PETRO

Double
blind RCT
in respect
to
dabigatran
;
unblinded
in respect
to
warfarin
and ASA

502

70.9 ±7.9
years in
patients with
CAD
68.0 ±8.8
years in those
without CAD

OUTCOMES MEASURED
The outcomes of interest in the clinical trials varied according to each study. However,
each study included outcomes, whether primary or secondary, that will be the focus of this
review.
In the RE-LY study, the primary outcome measured was incidence of stroke or systemic
embolism. The primary safety outcome was rate of major hemorrhage. Incidence of stroke was
documented by sudden onset of a focal neurologic deficit in a location consistent with the
territory of a major cerebral artery. The stroke was then categorized as ischemic, hemorrhagic, or
unspecified. Occurrence of a systemic embolism was documented through imaging, surgery, or
autopsy. Secondary outcomes consisted of major bleeding, hemorrhagic stroke, and mortality
rate. Major bleeding or hemorrhage was documented by reduction in hemoglobin of at least
2g/L, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ.
In the RE-COVER trial, the primary study outcome was 6-month incidence of recurrent,
symptomatic, objectively confirmed venous thromboembolism and related deaths. Symptoms
suggestive of recurrent venous thromboembolism were evaluated with the use of the same
diagnostic methods that had been used for the initial diagnosis. Secondary outcomes were major
bleeding events, acute coronary syndromes, other adverse events, and results of liver function
tests. Bleeding was defined as major if it was clinically overt and if it was associated with a
decrease in hemoglobin of at least 2g/L, resulted in the need for transfusion of 2 or more units of
red cells, if it involved a critical site, or if the bleeding was fatal.
In the PETRO study, the primary outcome addressed was frequency of bleeding events
classified as fatal or life threatening retroperitoneal, intracranial, intraocular, or intraspinal

bleeding; or bleeding requiring surgery or transfusion of greater than 2 units associated with a
reduction of hemoglobin greater than 2g/L. Secondary efficacy endpoints were incidence of
stroke defined as acute onset of focal neurologic deficit of vascular origin lasting greater than 24
hours and/or systemic thromboembolism defined as an acute non-intracerebral or noncoronary
vascular event.
RESULTS
All three randomized controlled trials evaluated the efficacy of dabigatran 150 mg twice
daily to prevent stroke in patients in AF or measured rates of major and minor bleeding
compared with dose adjusted warfarin.
In the RE-LY study a total of 18,113 patients were enrolled, all of which had a mean age
of 71 years and a mean CHADS2 score of 2.1 (the CHADS2 score is a measure of the risk of
stroke in which CHF, HTN, and age of 75 years or older, and DM are each given 1 point and
previous stroke or TIA are each given 2 points).8 The median duration of follow-up was 2.0
years with 99.9% of patients achieving complete follow-up. Rates of the primary outcome of
stroke or systemic embolism were 1.11% per year in the group who received 150 mg of
dabigatran twice daily and 1.69% per year in those who received dose adjusted warfarin. A
confidence interval of 95% and a P-value of <0.0001 for non-inferiority was used for this data.
The NNT was determined to be – 173, signifying that for every 173 patients treated with
dabigatran, 1 less patient experienced stroke or hemorrhage compared with warfarin. The
incidence of major bleeding was 3.11% per year in those who received dabigatran 150 mg twice
daily and 3.36% per year in the warfarin group. The occurrence of hemorrhagic stroke was
determined to be 0.38% per year in the warfarin group and 0.10% in the dabigatran group at a pvalue of <0.0001. Mortality rate was found to be 3.64% per year with 150 mg of dabigatran

twice daily, whereas warfarin mortality was 4.13% per year at a p-value of 0.13. Major vascular
events, major bleeding, and death comprised the net clinical benefit outcome. The rate of this
outcome in the warfarin group was 7.64% per year and 6.91% per year in those given 150 mg of
dabigatran at a CI of 95% and a p-value of 0.10 (Table 2). The NNH in this group was
determined to be -400, thus, for every 400 patients treated with dabigatran, one less patient had
an incidence of major bleeding, hemorrhagic stroke, or mortality compared to warfarin.
Table 2. Efficacy and Bleeding Outcomes of the RE-LY Study
Event

Stroke or
systemic
embolism
Major
Bleeding
Hemorrhagic
Stroke
Mortality
Rate
Net clinical
benefit

Dabigatran 150 mg
N= 6076

Dose Adjusted Warfarin
N= 6022

# of patients

%/year

P-value

# of patients

%/year

P-value

134

1.11

<0.0001

199

1.69

<0.0001

375

3.11

0.003

397

3.36

0.003

12

0.10

<0.0001

45

0.38

<0.0001

438

3.64

0.13

487

4.13

0.13

832

6.91

0.10

901

7.64

0.10

In the RE-COVER trial, a total of 2,564 patients were enrolled, with a total of 1,274
patients in the dabigatran 150 mg group and 1,265 in the warfarin group. Incidence of the
primary outcome, recurrent venous thromboembolism, occurred in 2.4% of patients who
received dabigatran and 2.1% of those who received warfarin at a CI of 95% and p-value of
<0.001. The NNT in this group was 334. For every 334 people treated with dabigatran, 1 more
person had an occurrence of confirmed venous thromboembolism, compared to warfarin.
Incidence of major bleeding, which is of more concern for this review, was found in 1.6% of
patients in the dabigatran 150 mg group and a slightly higher percentage of 1.9% of those in the

warfarin group. For every 334 people treated with dabigatran, one less person experienced major
bleeding, acute coronary symptoms, and/or elevated liver function tests in comparison to
warfarin. Sites of major bleeding for the dabigatran groups included gastrointestional (9 events),
urogenital (5), intraarticular (1), intramuscular (1) or another site (6). For the warfarin group,
major sites of bleeding included urogenital (6), gastrointestinal (5), intraarticular (4), intracranial
(3), intramuscular (3), or another site (4). A total of 5.6% of patients who received dabigatran
compared to 8.8% of patients who were given warfarin experienced major or clinically relevant
non-major bleeding (Table 3).
Table 3. Efficacy and Bleeding Outcomes of the RE-COVER Study
Outcome

Venous thromboembolism
or related death
Major Bleeding Events
Major or clinically
relevant non-major
bleeding

Dabigatran 150 mg
twice daily
(N=1274)
30 patients
2.4%

Warfarin

Confidence Interval

(N=1265)
27 patients
2.1%

95%

20 patients
1.6%
71 patients
5.6%

24 patients
1.9%
111 patients
8.8%

95%

95%

In the PETRO trial, 502 patients were randomized who had atrial fibrillation for a median
duration of 4 years. The primary outcome was frequency of bleeding events. In the 150 mg
dabigatran group without aspirin, 9% of patients reported clinically relevant bleeding with zero
thromboembolic events. In patients who received dose adjusted warfarin without aspirin, 5.7% of
patients experienced clinically relevant bleeding with also no reported thromboembolic events at
a p-value of 0.01 (Table 4). The NNH for this study was -8 signifying that for every 8 patients
treated with dabigatran without aspirin, 1 less patient experienced a bleeding event when
compared to dose adjusted warfarin without aspirin.

Table 4. Major or clinically relevant bleeding episodes and thromboembolic events in PETRO

Dabigatran 150
mg BID
Warfarin

Number of
patients

Major
Bleeding

Thromboembolic
Events

0

Clinical
Relevant plus
Major
Bleeding
9 (9%)

100
70

0

4 (5.7%)

0

0

Because in all three trials the data was dichotomous, the control event rate (CER),
experimental event rate (EER), absolute benefit increase (ABI), relative benefit increase (RBI),
number needed to treat (NNT) and number needed to harm (NNH) were each calculated. The
CER is the percentage of patients who responded to the dose adjusted warfarin whereas the EER
is the percentage who responded to the 150 mg dabigatran. The ABI is the increase of a good
event as a result of dabigatran. The RBI is the proportional increase in the rates of good
outcomes between the warfarin and dabigatran group. The results of number needed to treat and
number needed to harm determines the number of people needed to be treated to prevent 1 event
of stroke or embolic event or to cause 1 event of major hemorrhage. Table 5 represents this data
that was calculated for all three of the trials described above.
Table 5. Treatment analysis for patients receiving dabigatran versus warfarin for prevention of
stroke
Study

CER

EER

RBI

ABI

RE-LY

1.96%
3.36%
2.1%
1.90%
17.1%

1.11%
3.11%
2.4%
1.60%
15.0%

-34.3%
-7.4%
14.3%
-15.8%
-12.3%

-0.58%
-0.25%
3.00%
-3.00%
-21.0%

RE-COVER
PETRO

NNT and
NNH
-173 (NNT)
-400 (NNH)
334 (NNT)
-334 (NNH)
-8
(NNH)

DISCUSSION
Dabigatran etexilate is a prodrug of dabigatran, a reversible competitive inhibitor of
thrombin activity. Dabigatran is able to inhibit both free and clot bound thrombin, as well as
inhibit thrombin’s activation of platelets.9 The drug requires no laboratory monitoring and carries

minimal drug and food interactions when compared with warfarin, making dabigatran an
attractive alternative to patients and prescribers. The most common adverse events that have
been associated with the use of dabigatran are bleeding and gastrointestinal symptoms including
dyspepsia, nausea, diarrhea, abdominal pain, and gastrointestinal bleeding.10 The RE-LY study
demonstrated a statistically significant decrease in the rates of stroke and systemic embolism
when compared with warfarin. The RE-COVER and PETRO study each exemplified the safety
of dabigatran when compared to warfarin with a statistically significant decrease in major
bleeding events.
All three studies presented in this review can be termed valid for many reasons. They
were randomized controlled trials whose outcomes were presented as dichotomous data, and the
studies were double-blinded in regards to the dabigatran group. There were also a minimal
number of patients who were lost to follow-up. Because there was a small sample size of patients
in the PETRO dabigatran 150 mg group, the results may have been skewed.
CONCLUSION
This review indicates that dabigatran 150 mg twice a day is a safe and effective alternative to
warfarin to prevent stroke in patients with atrial fibrillation. In all three studies, dabigatran
150mg was found to be non-inferior to warfarin in respect to stroke prevention and incidence of
bleeding. In the RE-LY study, dabigatran 150 mg was found to be superior when to compared to
warfarin regarding rates of stroke and systemic embolism. Higher and lower doses of dabigatran
have been investigated, however, results showed that the lower doses were not as effective in
preventing stroke whereas higher doses had increased incidence of major bleeding rates. Future
studies should compare the efficacy of dabigatran versus another new oral thrombin inhibitor,
rivaroxaban, for the prevention of stroke in patients with AF.
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